Peter Lobie

Lobie Peter

  • Professor, Department of Pharmacology
  • Senior Principal Investigator, Cancer Science InstituteĀ of Singapore, National University of Singapore
Administrative Appointment(s)
  • Chair of Graduate Committee, Cancer Science Institute of Singapore, National University of Singapore
Joint Appointment(s)
  • Honorary Professor, University of Science and Technology of China, China
Academic Qualifications
  • PhD, Karolinska Institutet, Stockholm, Sweden
  • B.Med.Sci, University of Queensland, Australia
  • MBBS (Honours, First Class), University of Queensland, Australia
Research Interest(s)
  • Breast Cancer
  • TFF
  • Therapeutics
Recent Publications
  • 1. Bui NLC, Pandey V, Zhu T, Ma L, Basappa, Lobie PE. 2018 Feb. Bad phosphorylation as a target of inhibition in oncology. Cancer Letters. 415:177-186. doi: 10.1016/j.canlet.2017.11.017.
  • 2. Fielder GC, Yang TWS, Razdan M, Li Y, Lu J, Perry JK, Lobie PE, Liu DX. 2018 Jan. The GDNF Family: A Role in Cancer?. Neoplasia. 20(1):99-117. doi: 10.1016/j.neo.2017.10.010.
  • 3. Ong MS, Cai W, Yuan Y, Leong HC, Tan TZ, Mohammad A, You ML, Arfuso F, Goh BC, Warrier S et al. 2017 Dec. ' Lnc '-ing Wnt in female reproductive cancers: therapeutic potential of long non-coding RNAs in Wnt signalling. British Journal of Pharmacology. 174(24):4684-4700. doi: 10.1111/bph.13958.
  • 4. Chen L, Yuan Y, Kar S, Kanchi MM, Arora S, Kim JE, Koh PF, Yousef E, Samy RP, Shanmugam MK et al. 2017 Nov. PPARĪ³ Ligand-induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers. Mol Cancer Ther. 16(11):2528-2542. doi: 10.1158/1535-7163.MCT-16-0739.
  • 5. Tan S, Ding K, Chong Q-Y, Zhao J, Liu Y, Shao Y, Zhang Y, Yu Q, Xiong Z, Zhang W et al. 2017 Aug. Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells. Journal of Biological Chemistry. 292(33):13551-13564. doi: 1074/jbc.M117.780973.